This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Graft Versus Host Disease (GvHD) Treatment Market

Demand for Corticosteroid-based (GvHD) Treatment to experience noteworthy incline

Graft Versus Host Disease (GvHD) Treatment Market by Product, Disease & Region - Forecast 2022 - 2032

Graft Versus Host Disease (GvHD) Treatment Market Outlook (2022-2032)

[311 Pages Report] The global graft versus host disease (GvHD) treatment market is expected to secure US$ 5,655.37 Million in 2032 while expanding at a CAGR of 8.3%.

The market is experiencing a steady growth in corticosteroids and combination therapies for graft-versus-host disease in HCT patients boosting the market for (GvHD) treatment. The market is likely to hold a value of US$ 2,547.86 Million in 2022. From 2016-21, the market displayed a growth rate of 7.8%.

Allogeneic hematopoietic cell transplant patients may benefit from recent advancements in overall survival and acute graft-versus-host disease ((GVHD)) severity levels, however, there are a number of challenges that must be addressed. In addition, newer medications such as Jakafi and Rezurock have recently been approved for the prevention and treatment of chronic (GVHD) and may provide a greater benefit than older medications.

Data Points

Key Statistics

Projected Market Value (2022)

US$ 2,547.86 Million

Anticipated Forecast Value (2032)

US$ 5,655.376 Million

Estimated Growth Rate (2022-2032)

8.3% CAGR

For treating adults and pediatric patients with GVHD, Orencia (abatacept) was approved by the U.S. Food and Drug Administration in December 2021. In addition to treating autoimmune disorders, Orencia is also used to prevent them. T-cells are a key component of acute (GVHD), and this drug circumvents their attack by specifically binding to and modulating one of the main costimulation signals sent by these cells.

This prevents a full activation of T-cells, which prevents acute (GVHD) from occurring. A number of new approaches are being evaluated by doctors in order to prevent (GVHD) in the future.

Further, approval of Orencia will make stem cell transplants more accessible to a larger number of cancer patients and people with blood disorders, particularly people from diverse ethnic backgrounds. To improve treatment response, future treatments may include immunosuppression and other treatment agents, such as regenerative or tissue-repairing agents to the market.

Customize this Report

Let us know your requirement to get
100% FREE customization

Factors Contributing To The Growth Of The Global Graft Versus Host Disease (Gvhd) Treatment Market?

A healthy CAGR is expected to be observed for graft versus host disease treatment during the forecast period. As innovative technologies are developed, and cancer patients seek out chemotherapy treatments, the graft versus host disease ((GvHD)) treatment market is expected to grow from 2022-2032.

Cancer patients who are treated with chemotherapy are the main driving force behind the graft versus host disease ((GvHD)) market at present. Increasing bone marrow transplants to treat specific cancers is also fueling the global graft versus host disease market.

Human health products have become increasingly innovative and effective in recent decades. Growth in graft versus host disease ((GvHD)) will be considerably impacted by the use of allogeneic stem cell transplants.

In order to stay competitive, key players focus on introducing new drugs to the market. As a result of the high investments made by the public and private sectors in R&D technology and infrastructure, it is expected that the market will be provided with lucrative opportunities in the near future.

A global economy that focuses on advancing technology and innovation has the potential to restore growth and ensure the future competitiveness of the pharmaceutical industry by investing in innovation and research.

What Factors are impeding the Global Market for Graft Versus Host Disease (GvHD) Treatments?

Global graft versus host disease ((GvHD)) market growth is likely to be hindered by costs associated with recent clinical trials and authorizations. Using steroids in the treatment of (GvHD) immune diseases, skin diseases, and other conditions may result in side effects such as glucose levels increasing, fluid retention, mood problems, appetite disorders, and stomach pain.

The use of steroids over a long period of time has been linked to diabetes, infection, muscle weakness, and even cancer.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Why Is The Global Market For Graft Versus Host Disease (Gvhd) Treatments Expected To Dominate North America?

As per the analysis, the global graft versus host disease (GvHD) treatment market is expected to be dominated by North America during the forecast period. In 2022, the region is expected to secure about 34% of the total market share. As a result of a well-established medical infrastructure and the proliferation of major key players in the region, the region has become a dominant market for (GvHD) treatments.

The United States is expected to contribute the most to the development of the market during the forecast period. Growing awareness of (GVHD) has boosted the market for (GvHD) treatments in this region. New medicines are expected to propel the market growth during the forecast period. Additionally, the regulatory authority's approval for various medicines in the market also contributes to the growth of the region.

For instance, on September 22, 2021, the FDA approved Ruxolitinib for chronic graft-versus-host disease ((GVHD)) in adults and children over 12 years of age who have failed one or more lines of systemic therapy. REACH-3 (NCT03112603) evaluated ruxolitinib's efficacy as a treatment for corticosteroid-refractory chronic (GVHD) after allogeneic stem cell transplantation compared with the best available therapy (BAT) on the market.

How Has Europe Contributed To The Growth Of The Global Graft Versus Host Disease Treatment Market?

According to the analysis, Europe is projected to be the second-largest market during the forecast period. It is estimated that the region will hold 21% of the total market share in 2022. The growth of the market can be attributed to the rapid development of the food and beverage sector in the region.

Growing awareness, the availability of chemotherapies, and the adoption of advanced cancer treatment technologies drive the market for graft versus host disease ((GvHD)) treatment in these regions. In addition, rise in the aging population, scientific advancements, and clinical trials are expected to grow the market for GvHD treatment in the market.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-Wise Insights

What are the Most Effective Products on the Market for Treating GvHD?

According to Future Market Insights, monoclonal antibodies are expected to gain significant market share in the upcoming years. With the rapid development of pharmaceuticals and clinical trials, along with the expanding treatment for chronic diseases, the worldwide market is set for continued expansion in the near future.

The increasing number of cancer cases in various regions has fuelled the growth of this market in recent years. Due to their specialization in targeted cancer therapies in the medical sector, monoclonal antibodies are in high demand due to their unique properties.

Furthermore, some monoclonal antibodies are also immunotherapies since they are effective in fighting cancer by turning the immune system against the disease. These treatment types are therefore growing in the market.

How likely is it that the market for Acute Graft Versus Host Disease (GvHD) will grow in the future?

The use of various treatments for GvHD is expected to drive the market and account for the greatest share in 2022. Globally, the market is expected to grow at a significant CAGR, attracting private and public investments to this market.

Ruxolitinib is becoming more widely used as an alternative treatment option for acute graft versus host disease ((GvHD)), which reduces the need for hospitalization unless there are complications. Increasing immunosuppression is often successfully achieved through the administration of oral or intravenous steroid medications.

The severe complications of acute graft-versus-host disease ((GVHD)) continue to hinder the success of allogeneic hematopoietic stem cell transplants (HSCTs). As a treatment when prophylaxis fails or remains suboptimal, the ability to prevent (GVHD) prophylaxis is crucial. The most commonly prescribed regimen for prophylaxis of (GVHD) still consists of a calcineurin inhibitor in combination with methotrexate.

How are Start-Up Companies Playing a Role in Augmenting Sales of Graft Versus Host Disease (GvHD) Treatment?

Healthcare continues to be a flourishing sector, and the demand for safe and effective medications is on the rise. Numerous innovative medicine solutions have been introduced in the medical field to reduce side effects and improve long-term outcomes, including the incorporation of graft versus host disease (GvHD) treatment. As start-ups realize its potential, they are firmly establishing themselves on the global market.

Some notable graft versus host disease start-up manufacturers are as follows:

  • Astellas Pharma, founded in 2005 as a Japanese multinational pharmaceutical company formed from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. A number of drugs have been developed by the company that are used effectively to treat (GVHD) diseases and other chronic diseases.
  • Mesoblast Ltd, a U.K-based graft versus host disease (GvHD) treatment manufacturer, offers allogeneic cellular medicines are being developed and commercialized by Mesoblast using its proprietary technology platform to treat diseases that are resistant to conventional treatments and in which inflammation is a significant factor. Among the Company's Phase 3 products are remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-a(GVHD)), and for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection; REVASCOR® for severe chronic heart failure; and MPC-06-ID for degenerative disc disease-related chronic low back pain.
  • Equillium, Inc. develops unmet medical needs in the treatment of severe autoimmune and inflammatory disorders by leveraging a deep understanding of immunobiology. The company is situated in California, United States and was foun in 2017. A Phase 3 study is currently underway for graft-versus-host disease patients and a Phase 1b trial has been initiated for patients with lupus/lupus nephritis patients. An alopecia areata study is expected to begin enrolling patients in the second half of 2022 with EQ101, a first-in-class tri-specific cytokine inhibitor that targets IL-2, IL-9, and IL-15.

Competition Analysis

Key players in the global graft versus host disease (GvHD) treatment market include Sanofi, Equillium, Inc., Novartis AG, Neovii Biotech GmbH,Merck & Co., Astellas Pharma Inc.,Soligenix, Inc., Mesoblast Ltd, Pfizer, Takeda Pharmaceutical, Abbott, and others.

  • In March 2022, Equillium, Inc. announced the initiation of the EQUATOR study, a pivotal Phase 3 clinical study of itolizumab in patients with acute graft-versus-host disease (GvHD)). As first-line therapy for (GvHD) combined with corticosteroids, itolizumab will be compared with placebo in a randomized, double-blind study.
  • In May 2022, Novartis announced the approval of European Commission (EC) for Jakavi (ruxolitinib) for the treatment of patients aged 12 years and older with acute or chronic (GvHD) who have suffered from an insufficient response to corticosteroids or other systemic treatments. A new way to manage (GvHD) that is debilitating and life-threatening is now possible with Jakavi, which qualifies as a new option for healthcare providers and patients.

Report Scope

Growth Rate (2022-2032)

8.3% CAGR

Market Value in 2022

US$ 2,547.86 Million

Market Value in 2032

US$ 5,655.37 Million

Base Year for Estimation

2021

Historical Data

2016-2021

Forecast Period

2022-2032

Quantitative Units

USD Million for Value

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking,

Competitive Landscape, Growth Factors, Trends, and

Pricing Analysis

Segments Covered

  • Product Type
  • Disease Type
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

  • Sanofi
  • Equillium, Inc.
  • Novartis AG
  • Neovii Biotech GmbH
  • Merck & Co.
  • Astellas Pharma Inc.
  • Soligenix, Inc.
  • Mesoblast Ltd
  • Pfizer
  • Takeda Pharmaceutical
  • Abbott

Customization Scope

Available upon Request

Key Segments Profiled In The Global Graft Versus Host Disease (Gvhd) Treatment Market

Graft Versus Host Disease (GvHD) Treatment Market by Product:

  • Monoclonal antibodies Graft Versus Host Disease (GvHD) Treatment
  • mTOR inhibitors Graft Versus Host Disease (GvHD) Treatment
  • Tyrosine kinase inhibitors Graft Versus Host Disease (GvHD) Treatment
  • Thalidomide Graft Versus Host Disease (GvHD) Treatment
  • Etanercept Graft Versus Host Disease (GvHD) Treatment

Graft Versus Host Disease (GvHD) Treatment Market by Disease:

  • Acute Graft Versus Host Disease (a(GvHD))
  • Chronic Graft Versus Host Disease (c(GvHD))

Graft Versus Host Disease (GvHD) Treatment Market by Region:

  • North America Graft Versus Host Disease (GvHD) Treatment Market
  • Latin America Graft Versus Host Disease (GvHD) Treatment Market
  • Europe Graft Versus Host Disease (GvHD) Treatment Market
  • Asia Pacific Graft Versus Host Disease (GvHD) Treatment Market
  • Middle East & Africa Graft Versus Host Disease (GvHD) Treatment Market

Frequently Asked Questions

FMI projects the global graft versus host disease (GvHD) treatment market to expand at an 8.3% value CAGR by 2032

North America is expected to be the most opportunistic graft versus host disease (GvHD) treatment market, accumulating 34% revenue in 2022

Sanofi, Equillium, Inc., Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., Mesoblast Ltd, Pfizer, Takeda Pharmaceutical, Abbott, and others. Are among the prominent companies recognized globally in graft versus host disease (GvHD) treatment.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2016-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Disease

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Disease, 2016-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease, 2022-2032

        5.3.1. Acute graft versus host disease (aGvHD)

        5.3.2. Chronic graft versus host disease (cGvHD)

    5.4. Y-o-Y Growth Trend Analysis By Disease, 2016-2021

    5.5. Absolute $ Opportunity Analysis By Disease, 2022-2032

6. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Product

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Product, 2016-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product, 2022-2032

        6.3.1. mTOR inhibitors Graft Versus Host Disease GvHD Treatment

        6.3.2. Tyrosine kinase inhibitors Graft Versus Host Disease GvHD Treatment

        6.3.3. Monoclonal antibodies Graft Versus Host Disease GvHD Treatment

        6.3.4. Etanercept Graft Versus Host Disease GvHD Treatment

        6.3.5. Thalidomide Graft Versus Host Disease GvHD Treatment

        6.3.6. Others Graft Versus Host Disease GvHD Treatment

    6.4. Y-o-Y Growth Trend Analysis By Product, 2016-2021

    6.5. Absolute $ Opportunity Analysis By Product, 2022-2032

7. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021

    7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        8.2.1. By Country

            8.2.1.1. U.S.

            8.2.1.2. Canada

        8.2.2. By Disease

        8.2.3. By Product

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Disease

        8.3.3. By Product

    8.4. Key Takeaways

9. Latin America Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Disease

        9.2.3. By Product

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Disease

        9.3.3. By Product

    9.4. Key Takeaways

10. Europe Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Disease

        10.2.3. By Product

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Disease

        10.3.3. By Product

    10.4. Key Takeaways

11. Asia Pacific Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Malaysia

            11.2.1.5. Singapore

            11.2.1.6. Australia

            11.2.1.7. Rest of Asia Pacific

        11.2.2. By Disease

        11.2.3. By Product

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Disease

        11.3.3. By Product

    11.4. Key Takeaways

12. MEA Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of MEA

        12.2.2. By Disease

        12.2.3. By Product

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Disease

        12.3.3. By Product

    12.4. Key Takeaways

13. Key Countries Market Analysis

    13.1. U.K.

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2021

            13.1.2.1. By Disease

            13.1.2.2. By Product

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2021

            13.2.2.1. By Disease

            13.2.2.2. By Product

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2021

            13.3.2.1. By Disease

            13.3.2.2. By Product

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2021

            13.4.2.1. By Disease

            13.4.2.2. By Product

    13.5. Rest of Latin America

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2021

            13.5.2.1. By Disease

            13.5.2.2. By Product

    13.6. Germany

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2021

            13.6.2.1. By Disease

            13.6.2.2. By Product

    13.7. U.K.

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2021

            13.7.2.1. By Disease

            13.7.2.2. By Product

    13.8. France

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2021

            13.8.2.1. By Disease

            13.8.2.2. By Product

    13.9. Spain

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2021

            13.9.2.1. By Disease

            13.9.2.2. By Product

    13.10. Italy

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2021

            13.10.2.1. By Disease

            13.10.2.2. By Product

    13.11. Rest of Europe

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2021

            13.11.2.1. By Disease

            13.11.2.2. By Product

    13.12. China

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2021

            13.12.2.1. By Disease

            13.12.2.2. By Product

    13.13. Japan

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2021

            13.13.2.1. By Disease

            13.13.2.2. By Product

    13.14. South Korea

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2021

            13.14.2.1. By Disease

            13.14.2.2. By Product

    13.15. Malaysia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2021

            13.15.2.1. By Disease

            13.15.2.2. By Product

    13.16. Singapore

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2021

            13.16.2.1. By Disease

            13.16.2.2. By Product

    13.17. Australia

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2021

            13.17.2.1. By Disease

            13.17.2.2. By Product

    13.18. Rest of Asia Pacific

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2021

            13.18.2.1. By Disease

            13.18.2.2. By Product

    13.19. GCC Countries

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2021

            13.19.2.1. By Disease

            13.19.2.2. By Product

    13.20. South Africa

        13.20.1. Pricing Analysis

        13.20.2. Market Share Analysis, 2021

            13.20.2.1. By Disease

            13.20.2.2. By Product

    13.21. Israel

        13.21.1. Pricing Analysis

        13.21.2. Market Share Analysis, 2021

            13.21.2.1. By Disease

            13.21.2.2. By Product

    13.22. Rest of MEA

        13.22.1. Pricing Analysis

        13.22.2. Market Share Analysis, 2021

            13.22.2.1. By Disease

            13.22.2.2. By Product

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Disease

        14.3.3. By Product

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Novartis AG

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. Merck & Co.

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. Neovii Biotech GmbH

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. Astellas Pharma Inc.

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Soligenix

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Mesoblast Ltd

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Pfizer

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. Sanofi

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. Takeda Pharmaceutical

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. Abbott

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Market Value (US$ Mn) Forecast by Region, 2016-2032

Table 02: Global Market Value (US$ Mn) Forecast by Disease, 2016-2032

Table 03: Global Market Value (US$ Mn) Forecast by Product, 2016-2032

Table 04: North America Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 05: North America Market Value (US$ Mn) Forecast by Disease, 2016-2032

Table 06: North America Market Value (US$ Mn) Forecast by Product, 2016-2032

Table 07: Latin America Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 08: Latin America Market Value (US$ Mn) Forecast by Disease, 2016-2032

Table 09: Latin America Market Value (US$ Mn) Forecast by Product, 2016-2032

Table 10: Europe Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 11: Europe Market Value (US$ Mn) Forecast by Disease, 2016-2032

Table 12: Europe Market Value (US$ Mn) Forecast by Product, 2016-2032

Table 13: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 14: Asia Pacific Market Value (US$ Mn) Forecast by Disease, 2016-2032

Table 15: Asia Pacific Market Value (US$ Mn) Forecast by Product, 2016-2032

Table 16: MEA Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 17: MEA Market Value (US$ Mn) Forecast by Disease, 2016-2032

Table 18: MEA Market Value (US$ Mn) Forecast by Product, 2016-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Market Value (US$ Mn) by Disease, 2022-2032

Figure 02: Global Market Value (US$ Mn) by Product, 2022-2032

Figure 03: Global Market Value (US$ Mn) by Region, 2022-2032

Figure 04: Global Market Value (US$ Mn) Analysis by Region, 2016-2032

Figure 05: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 06: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 07: Global Market Value (US$ Mn) Analysis by Disease, 2016-2032

Figure 08: Global Market Value Share (%) and BPS Analysis by Disease, 2022-2032

Figure 09: Global Market Y-o-Y Growth (%) Projections by Disease, 2022-2032

Figure 10: Global Market Value (US$ Mn) Analysis by Product, 2016-2032

Figure 11: Global Market Value Share (%) and BPS Analysis by Product, 2022-2032

Figure 12: Global Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 13: Global Market Attractiveness by Disease, 2022-2032

Figure 14: Global Market Attractiveness by Product, 2022-2032

Figure 15: Global Market Attractiveness by Region, 2022-2032

Figure 16: North America Market Value (US$ Mn) by Disease, 2022-2032

Figure 17: North America Market Value (US$ Mn) by Product, 2022-2032

Figure 18: North America Market Value (US$ Mn) by Country, 2022-2032

Figure 19: North America Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 22: North America Market Value (US$ Mn) Analysis by Disease, 2016-2032

Figure 23: North America Market Value Share (%) and BPS Analysis by Disease, 2022-2032

Figure 24: North America Market Y-o-Y Growth (%) Projections by Disease, 2022-2032

Figure 25: North America Market Value (US$ Mn) Analysis by Product, 2016-2032

Figure 26: North America Market Value Share (%) and BPS Analysis by Product, 2022-2032

Figure 27: North America Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 28: North America Market Attractiveness by Disease, 2022-2032

Figure 29: North America Market Attractiveness by Product, 2022-2032

Figure 30: North America Market Attractiveness by Country, 2022-2032

Figure 31: Latin America Market Value (US$ Mn) by Disease, 2022-2032

Figure 32: Latin America Market Value (US$ Mn) by Product, 2022-2032

Figure 33: Latin America Market Value (US$ Mn) by Country, 2022-2032

Figure 34: Latin America Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 37: Latin America Market Value (US$ Mn) Analysis by Disease, 2016-2032

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Disease, 2022-2032

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Disease, 2022-2032

Figure 40: Latin America Market Value (US$ Mn) Analysis by Product, 2016-2032

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Product, 2022-2032

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 43: Latin America Market Attractiveness by Disease, 2022-2032

Figure 44: Latin America Market Attractiveness by Product, 2022-2032

Figure 45: Latin America Market Attractiveness by Country, 2022-2032

Figure 46: Europe Market Value (US$ Mn) by Disease, 2022-2032

Figure 47: Europe Market Value (US$ Mn) by Product, 2022-2032

Figure 48: Europe Market Value (US$ Mn) by Country, 2022-2032

Figure 49: Europe Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 52: Europe Market Value (US$ Mn) Analysis by Disease, 2016-2032

Figure 53: Europe Market Value Share (%) and BPS Analysis by Disease, 2022-2032

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Disease, 2022-2032

Figure 55: Europe Market Value (US$ Mn) Analysis by Product, 2016-2032

Figure 56: Europe Market Value Share (%) and BPS Analysis by Product, 2022-2032

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 58: Europe Market Attractiveness by Disease, 2022-2032

Figure 59: Europe Market Attractiveness by Product, 2022-2032

Figure 60: Europe Market Attractiveness by Country, 2022-2032

Figure 61: Asia Pacific Market Value (US$ Mn) by Disease, 2022-2032

Figure 62: Asia Pacific Market Value (US$ Mn) by Product, 2022-2032

Figure 63: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032

Figure 64: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 67: Asia Pacific Market Value (US$ Mn) Analysis by Disease, 2016-2032

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Disease, 2022-2032

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Disease, 2022-2032

Figure 70: Asia Pacific Market Value (US$ Mn) Analysis by Product, 2016-2032

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Product, 2022-2032

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 73: Asia Pacific Market Attractiveness by Disease, 2022-2032

Figure 74: Asia Pacific Market Attractiveness by Product, 2022-2032

Figure 75: Asia Pacific Market Attractiveness by Country, 2022-2032

Figure 76: MEA Market Value (US$ Mn) by Disease, 2022-2032

Figure 77: MEA Market Value (US$ Mn) by Product, 2022-2032

Figure 78: MEA Market Value (US$ Mn) by Country, 2022-2032

Figure 79: MEA Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 82: MEA Market Value (US$ Mn) Analysis by Disease, 2016-2032

Figure 83: MEA Market Value Share (%) and BPS Analysis by Disease, 2022-2032

Figure 84: MEA Market Y-o-Y Growth (%) Projections by Disease, 2022-2032

Figure 85: MEA Market Value (US$ Mn) Analysis by Product, 2016-2032

Figure 86: MEA Market Value Share (%) and BPS Analysis by Product, 2022-2032

Figure 87: MEA Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 88: MEA Market Attractiveness by Disease, 2022-2032

Figure 89: MEA Market Attractiveness by Product, 2022-2032

Figure 90: MEA Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Hirschsprung Disease Treatment Market

Published : September 2017

Healthcare

Infectious Disease Diagnostics Market

Published : January 2016

Healthcare

Neurodegenerative Disease Market

Published : March 2022

Google translate

Graft Versus Host Disease (GvHD) Treatment Market